New Antibiotics & New Insights into Old Antibiotics
|
|
- Emery Davidson
- 5 years ago
- Views:
Transcription
1 New Antibiotics & New Insights into Old Antibiotics Louisiana Chapter of the American Academy of Pediatrics August 18, 2018 Baton Rouge, Louisiana John Bradley MD Rady Children s Hospital San Diego University of California, San Diego
2 Antibiotic Update: Disclosure Statement: John S. Bradley, MD Dr. Bradley has no personal financial relationship with any commercial interest that produces, markets, re-sells, or distributes antimicrobials. Dr. Bradley s employer, the University of California, has received research funds for clinical trials during the past 12 months for study of daptomycin, ceftolozane/tazobactam, tedizolid (Cubist/Merck), dalbavancin (Durata/Allergan), oritavancin, lefamulin (Melinta), colistin (NIH), piperacillin/tazobactam (CHOP) and ceftaroline (AstraZeneca, Pfizer, RCHSD Foundation) The Regents of the University of California hold consulting contracts with Cubist/Merck, AstraZeneca, Actavis/Allergan This presentation will include discussion of unapproved or off-label uses of pharmaceuticals.
3 Why Do We Need New Antibiotics? 1. Increasing antibiotic resistance! Skin, bone/joint: Staph aureus R: Clindamycin, methicillin Urinary tract: E. coli, Klebsiella R: Ampicillin, TMP/SMX, cefixime/cefotaxime Nosocomial infections: Pseudomonas, Acinetobacter, Stenotrophomonas R: Ceftaz, cefepime, meropenem, ciprofloxacin not so much of a need for new therapy of AOM or strep throat!
4 Why Do We Need New Antibiotics? 2. Oral therapy would be better than IV 3. Less frequent dosing Once daily would be nice Once weekly would even better for extended therapy 4. Less toxicity would be nice
5 Antibiotics for MRSA An 8 yo boy was playing baseball in empty field; later that evening noted to have a small area of erythema later over his elbow. No known trauma; unsure about bug bites. Small pustule formed over area with mild warmth and erythema. Seen by PMD in clinic with expression of pus with culture taken. Begun on Bactrim therapy and topical antibiotic ointment but with continued pain with increased swelling over the week
6 Antibiotics for MRSA Completed at least 8-9 days of therapy with Bactrim, but still developed new fever and significant drainage from area - at that point went to ED for further workup Admitted to our hospital for r/o septic elbow with soft tissue abscess/cellulitis Ortho consult for septic elbow; started on IV clindamycin (we have about 90% susceptibility for MSSA and MRSA locally); was drained in the OR; got better!!
7 Antibiotics for MRSA Report from Referring ER
8 Home Oral Therapy for MRSA Clindamycin? Intermediate (not fully susceptible) taking a chance as killing with clindamycin is concentration-dependent Erythromycin? Only bacteriostatic We don t usually use for invasive infection Tetracycline? Also bacteriostatic Intermediate, but he is over 7 yrs of age TMP-SMX? bactericidal, but He failed that already
9 Linezolid Antibiotics for MRSA Most microbiology labs include susceptibility to linezolid 98% of MRSA are susceptible Virtually 100% bioavailable 30 mg/kg/day divided tid FDA approved for children ~20 yrs ago Costly, even generic! Safe for short term (less than 2 weeks) of therapy, but long term associated with thrombocytopenia and neutropenia
10 Clindamycin vs. TMP-SMX for UNCOMPLICATED Skin Infections
11 Antibiotics for Uncomplicated MRSA Creech et al 2015 Patients were categorized as having Cellulitis (defined as inflammation of the skin and associated skin structures without signs of a drainable fluid collection) Abscess (defined as a circumscribed, drainable collection of pus), or Both (if lesions of both cellulitis and abscess were present) All abscesses were treated by means of incision and drainage
12 Clindamycin Susceptibility in MSSA and MRSA Across the USA
13 Clindamycin Susceptibility in MSSA and MRSA Across the USA Clindamycin % Susceptible Hospital MSSA MRSA Seattle Children s Rady San Diego Children s Primary Children s (Salt Lake City) Texas Children s (Houston, TX) Mercy KC Children s (Kansas City) Cincinnati Children s Sanford Children s (Sioux City, SD) LeBonheur Children s (Memphis, TN) Duke Children s (North Carolina) Morgan Stanley Children's (NY- Presbyterian) 71 63
14 Clindamycin Susceptibility in MSSA and MRSA: Shreveport
15 Oral Antibiotics for MRSA Take home messages: 1. Many MRSA strains are not susceptible to clindamycin (up to 40% in some regions) Most resistance occurs in strains that are ALSO resistant to erythromycin (binding site on MRSA is altered for BOTH classes) 2. Sometimes you just need drainage! 3. Bactrim/Septra should work for uncomplicated, drained Staph skin infections
16 Finally! New FDA-approved Beta-lactam IV Therapy for MRSA in Children Ceftaroline (Teflaro ) FDA Package Label: For 2 months of age and older for: Skin Community pneumonia Neonatal studies completed and submitted to FDA
17 Finally! New FDA-approved Beta-lactam IV Therapy for MRSA in Children Ceftaroline (Teflaro ) [Similar to cefotaxime/ceftriaxone]
18 Finally! New FDA-approved Beta-lactam IV Therapy for MRSA in Children Ceftaroline (Teflaro )
19 Finally! New FDA-approved Beta-lactam IV Therapy for MRSA in Children Ceftaroline (Teflaro )
20 Finally! New FDA-approved Beta-lactam IV Therapy for MRSA in Children No unexpected treatment failures or adverse events (toxicity) reported since approval in children This takes us back to the cefazolin days (beta-lactam therapy) for Staph aureus less toxic than vancomycin, do not need to follow renal function or drug levels No head-to-head comparisons with clindamycin for deeper Staph infections
21 Finally! New FDA-approved Beta-lactam IV Therapy for MRSA in Children Ceftaroline might be preferred in children with more serious MRSA infections when you worry about pushing the dose of vancomycin (MIC > 2) to toxicity (possibly used in combination with gentamicin) Ceftaroline might be preferred in regions with relatively high clindamycin resistance for those who wish to avoid vancomycin use FDA-approved only for skin and pneumonia
22 Daptomycin IV Therapy Approved for MRSA Skin Infections in Children Daptomycin (Cubicin ) Cubist/Merck Pediatric data (took 15 years after adult approval) Multi-center, evaluator-blinded trial in children 1-17 yrs old with complicated skin/skin structure infection Randomized 2:1, intravenous daptomycin vs standardof-care (SOC) for 14 days; oral switch was permitted after 24 hours Daptomycin dose (population PK-derived) yrs, 5 mg/kg; 7-11 yrs, 7 mg/kg; 2-6 yrs, 9 mg/kg; mos, 10 mg/kg Bradley J, Glasser C, Patino H, Arnold SR, Arrieta A, Congeni B, Daum RS, Kojaoghlanian T, Yoon M, Anastasiou D, Wolf DJ, Bokesch P. Daptomycin for Complicated Skin Infections: A Randomized Trial. Pediatrics Mar;139(3).
23 Daptomycin IV Therapy Approved for MRSA Skin Infections in Children Pediatric data The intent-to-treat population: 257 daptomycin and 132 SOC patients (primarily clindamycin or vancomycin) 35% had confirmed MRSA Clinical success rates 7-14 days after end-of-treatment) were similar for daptomycin (91%) and SOC (87%; 95% confidence interval for treatment difference: -3% to 11%) Treatment-related adverse events were similar between daptomycin (14%) and SOC (17%) Cautions for use in children less than one year!
24 New Antibiotics in Pediatric Clinical Trials for MRSA Approved for adults, under study in children: Dalbavancin (one IV dose equivalent to 10d vanc!)* Oritavancin (one IV dose equivalent to 10d vanc!) Telavancin (once daily) Tedizolid (once daily PO/IV safer than linezolid) Under study in adults and children: Lefamulin (protein synthesis inhibitor) *Gonzalez D, Bradley JS, Blumer J, Yogev R, Watt KM, James LP, Palazzi DL, Bhatt-Mehta V, Sullivan JE, Zhang L, Murphy J, Ussery XT, Puttagunta S, Dunne MW, Cohen-Wolkowiez M. Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age. Pediatr Infect Dis J Jul;36(7):
25 Antibiotics for MDR E. coli UTI What is an ESBL-E. coli organism? Are they taking over? Extended Spectrum Beta Lactamase Just the usual E. coli, but now resistant. These resistance enzymes are only active against beta-lactam antibiotics (penicillins and some cephalosporins), but not aminoglycosides, TMP-SMX, FQ, tetracyclines
26 Antibiotics for MDR E. coli UTI Remember when all Haemophilus and all E. coli were susceptible to ampicillin? Then came beta-lactamases (TEM, SHV, etc) and we needed to use chloramphenicol and second/third generation cephalosporins like ceftriaxone/cefotaxime IV, and cefixime/cefdinir PO
27 Antibiotics for MDR E. coli UTI Remember when all Haemophilus and all E. coli were susceptible to ceftriaxone? Then came extended spectrum betalactamases in enteric bacilli There are now over 200 sequenced variations of TEM, SHV etc, that are active against 3 rd generation cephalosporins, some more active than others In Pediatrics, still only 5-10% prevalence
28 Antibiotics for MDR E. coli UTI For treatment of most ESBL E. coli: Carbapenems (meropenem) IV/IM Piperacillin/tazobactam IV Aminoglycosides (gent, tobra) IV/IM Fluoroquinolones (ciprofloxacin) IV/PO It is OK to use oral ciprofloxaxin for ESBL UTI! Jackson MA, Schutze GE; COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics Nov;138(5).
29 ESBL s and Your Hospital s Antibiogram Cipro floxa cin 98
30 E. coli ESBL Susceptibility
31 Antibiotics for MDR E. coli UTI in Outpatient Children in the US Amoxicillin, Cephalexin, Cefixime TMP- SMX Fluoroquinolone (cipro) Meropenem, ertapenem Piptazo Gent, amikacin E. coli: ESBL-positive R 70% S 98% S 99% S 98% S 95% S Green = Oral Red = IV/IM Harris PN et al. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis Apr;15(4):
32 Antibiotics for ESBL E. coli UTI For oral therapy of UTI: Check to see if TMP-SMX susceptible, then Check to see if ciprofloxacin susceptible, then You might need to go to IV/IM therapy For outpatients, once daily IM/IV therapy can be provided with ertapenem or amikacin as a last option
33 Antibiotic Selection for Increasingly Resistant Gm Neg Bacilli AAP Nelson s Antibiotic Therapy 2018
34 Antibiotics for MDR E. coli UTI New antibiotics approved for adults, under study in children (More are under study) Ceftazidime/avibactam Ceftolozane/tazobactam Meropenem/vaborbactam Plazomicin With stewardship, we all hope to decrease resistance! By federal law, every antibiotic approved for adults MUST also be studied in children (when they will be used in children): Pediatric Research Equity Act
35 Questions????
36 How We Select the Dose (Neonates) % of simulated patients achieving %ft>mic target of 60% % of patients achieving %ft>mic target GA 28 weeks GA 30 weeks GA 32 weeks GA 34 weeks GA 36 weeks GA 38 weeks 0 4 mg/kg, 2 hr inf, q8h 6 mg/kg, 2 hr inf, q8h 8 mg/kg, 2 hr inf, q8h 10 mg/kg, 2 hr inf, q8h 12 mg/kg, 2 hr inf, q8h 4 mg/kg, 1.5 hr inf, q8h 6 mg/kg, 1.5 hr inf, q8h 8 mg/kg, 1.5 hr inf, q8h 10 mg/kg, 1.5 hr inf, q8h 4 mg/kg, 1 hr inf, q8h GA 40 weeks 0-1 month old GA 28 weeks GA 30 weeks GA 32 weeks GA 34 weeks GA 36 weeks GA 38 weeks 1-2 months old 6 mg/kg, 1 hr inf, q8h GA 40 weeks 0-1 month old GA 28 weeks GA 30 weeks GA 32 weeks GA 34 weeks GA 36 weeks GA 38 weeks 1-2 months old 8 mg/kg, 1 hr inf, q8h GA 40 weeks 0-1 month old GA 28 weeks GA 30 weeks GA 32 weeks GA 34 weeks GA 36 weeks GA 38 weeks 1-2 months old 10 mg/kg, 1 hr inf, q8h GA 40 weeks 0-1 month old GA 28 weeks GA 30 weeks GA 32 weeks GA 34 weeks GA 36 weeks GA 38 weeks 1-2 months old 12 mg/kg, 1.5 hr inf, q8h 12 mg/kg, 1 hr inf, q8h GA 40 weeks 0-1 month old 1-2 months old
New Antibiotics & New Insights into Old Antibiotics
New Antibiotics & New Insights into Old Antibiotics Louisiana Chapter of the American Academy of Pediatrics August 18, 2018 Baton Rouge, Louisiana John Bradley MD Rady Children s Hospital San Diego University
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationInitial Management of Infections in the Era of Enhanced Antimicrobial Resistance
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationStaph Cases. Case #1
Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling
More informationEinheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
More informationPerichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAntimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More information* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
More informationAntimicrobials Update
Antimicrobials Update Rosie Amini, PharmD. BCPS Antimicrobial Stewardship Program Coordinator Swedish Medical Center Disclosures: Dr. Amini has no significant financial interest in any of the products
More informationMrsa abscess and cellulitis
Search Mrsa abscess and cellulitis An abscess is a collection of pus that has built up within the tissue of the body. Signs and symptoms of abscesses include redness, pain, warmth, and swelling. The. Staph
More informationSkin and Soft Tissue Infections Emerging Therapies and 5 things to know
2011 MFMER slide-1 Skin and Soft Tissue Infections Emerging Therapies and 5 things to know Aaron Tande, MD Assistant Professor of Medicine October 27, 2017 Division of INFECTIOUS DISEASES 2011 MFMER slide-2
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationDiscussion Points. Decisions in Selecting Antibiotics
Antibiotics in Acute Care Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More information10/13/14. Low: not well absorbed. Good: [blood and tissue] < than if given IV. High: > 90% absorption orally
Low: not well absorbed PO agent not for serious infection nitrofurantoin Good: [blood and tissue] < than if given IV [Therapeutic] in excess of [effective] eg. cephalexin High: > 90% absorption orally
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin
More informationPreserve the Power of Antibiotics
PROVIDERInsight News for providers in Northeast Nebraska April 2016 Preserve the Power of Antibiotics Antimicrobial stewardship interventions have been proven to improve individual patient outcomes, reduce
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationAntimicrobial Stewardship Program
Antimicrobial Stewardship Program David R. Woodard, MSc, FSHEA, CIC CDC: Antibiotic Resistance Threats in the United States, 2013 http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ CDC Threat Levels
More informationLEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES
LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationFelipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare
Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare 100% of all wounds will yield growth If you get a negative culture you something is wrong! Pseudomonas while ubiquitous does
More informationß-lactams. Sub-families. Penicillins. Cephalosporins. Monobactams. Carbapenems
β-lactams ß-lactams Sub-families Penicillins Cephalosporins Monobactams Carbapenems ß-lactams Mode of action PBPs = Trans/Carboxy/Endo- peptidases PBP binding (Penicillin-Binding Proteins) activation of
More informationProceedings of the 13th International Congress of the World Equine Veterinary Association WEVA
www.ivis.org Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA October 3-5, 2013 Budapest, Hungary Reprinted in IVIS with the Permission of the WEVA Organizers
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationChoosing the Best Antibiotic in Problem Outpatient Infectious Disease Cases
Choosing the Best Antibiotic in Problem Outpatient Infectious Disease Cases Dr. Earl Rubin Associate Professor Department of Pediatrics Division of Infectious Diseases Montreal Children s Hospital Disclosures
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationRational use of antibiotics
Rational use of antibiotics Uga Dumpis MD, PhD,, DTM Stradins University Hospital Riga, Latvia ugadumpis@stradini.lv BALTICCARE CONFERENCE, PSKOV, 16-18.03, 18.03, 2006 Why to use antibiotics? Prophylaxis
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationInfectious Disease: Drug Resistance Pattern in New Mexico
Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?
More informationAntimicrobials. Antimicrobials
Antimicrobials For more than 50 years, antibiotics have come to the rescue by routinely producing rapid and long-lasting miracle cures. However, from the beginning antibiotics have selected for resistance
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationEffectiv. q3) Purpose of Policy. Pharmacy: Antimicrobial subcommp&tittee of
Name ofpolicynupolicy:mber: Department: Approving Officer: Responsible Agent: Scope: Protected Antimicrobials 3364-133-106 Pharmacy: Antimicrobial subcommp&tittee of Chief Executive Officer Director of
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationBad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016
Pharmacist Learning Objectives Antimicrobial Resistance Julie Giddens Pharm D, BCPS Infectious Disease Clinical Pharmacist OSF Saint Francis Medical Center Peoria, IL The speaker has no conflicts to disclose
More informationAntimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationResponsible use of antibiotics
Responsible use of antibiotics Uga Dumpis MD, PhD Department of Infectious Diseases and Infection Control Pauls Stradiņs Clinical University Hospital Challenges in the hospitals Antibiotics are still effective
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationSurveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler
Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level janet hindler At the conclusion of this talk, you will be able to Describe CLSI M39-A3 recommendations
More informationCell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification
Cell Wall Weakeners Antimicrobials: Drugs that Weaken the Cell Wall Beta Lactams Penicillins Cephalosporins Carbapenems Aztreonam Vancomycin Teicoplanin Bacterial Cell Wall Bacterial cytoplasm is hypertonic
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationRational management of community acquired infections
Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationINFECTIOUS DISEASE ANTIMICROBIAL REVIEW. Michelle Aguirre Janel Liane Cala PGY1 Pharmacy Practice Residents Medical Center Hospital
INFECTIOUS DISEASE ANTIMICROBIAL REVIEW Michelle Aguirre Janel Liane Cala PGY1 Pharmacy Practice Residents Medical Center Hospital Objectives Review basic microbiology of organisms Implement MCH Antibiogram
More informationCopyright 2012 Diabetes In Control, Inc. For permission to reprint, please contact Heather Moran, Production Editor, at
Malignant Otitis Externa Inflammation and damage at the base of the skull due to an untreated outer ear P. aeruginosa most common organism Yellow-green drainage from the ear Odor Fever Deep inner ear pain
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationThe role of new antibiotics in the treatment of severe infections: Safety and efficacy features
The role of new antibiotics in the treatment of severe infections Safety and efficacy features Christian Eckmann Hannover, Germany The role of new antibiotics in the treatment of severe infections: Safety
More informationClindamycin coverage streptococcus
Clindamycin coverage streptococcus Oct 12, 2017. While clindamycin and erythromycin were at one time uniformly active against group B streptococci, resistance has been increasing. One large. We assessed
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationOptimizing Antibiotic Treatment of Skin and Soft Tissue Infections
Optimizing Antibiotic Treatment of Skin and Soft Tissue Infections 15th Annual Rocky Mountain Hospital Medicine Symposium November 6, 2017 Tim Jenkins, MD Director, Antibiotic Stewardship Program Denver
More informationMRSA What Are Our Treatment Options and How Do We Choose the Right One?
MRSA What Are Our Treatment Options and How Do We Choose the Right One? Kristi Traugott, PharmD, BCPS Clinical Pharmacy Specialist Infectious Diseases University Health System San Antonio, TX October 25,
More information